Position in ABBV
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$1,474,107
+$209,838 QoQ
Shares Held
5,858
+0.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#2,190
of 4,153 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Banque Transatlantique SA holds $103,275,926 across 11 Drug Manufacturers - General names. ABBV ranks #5 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
49,374 | $59,220,661 | |
| 2 | JNJ |
Johnson & Johnson
|
90,610 | $23,012,221 | |
| 3 | AZN |
Astrazeneca PLC
|
63,714 | $12,081,448 | |
| 4 | MRK |
Merck & Co., Inc.
|
35,317 | $4,538,234 | |
| 5 | ABBV |
AbbVie Inc.
This page
|
5,858 | $1,474,107 | |
| 6 | AMGN |
Amgen Inc
|
3,698 | $1,339,119 | |
| 7 | PFE |
Pfizer Inc
|
27,165 | $654,133 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
4,060 | $512,940 |
All Filings in ABBV
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,474,107 | 5,858 | Shares | Defined | 2026-07-30 | |
| 2026-03-31 | $1,264,269 | 5,813 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $184,619 | 808 | Shares | Defined | 2026-02-26 | |
| 2025-09-30 | $256,777 | 1,109 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $215,133 | 1,159 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $251,424 | 1,200 | Shares | Defined | 2025-09-09 | |
| 2024-12-31 | $213,240 | 1,200 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||